DOCSLIB.ORG

Supplementary Information Simplexviruses Successfully Adapt

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Information Simplexviruses Successfully Adapt Supplementary Information Simplexviruses successfully adapt to their host by fine-tuning immune responses Alessandra Mozzi, Rachele Cagliani, Chiara Pontremoli, Diego Forni, Irma Saulle, Marina Saresella, Uberto Pozzoli, Mario Clerici, Mara Biasin, Manuela Sironi Supplementary Figures: Figure S1. Positive selection in UL26, UL29, UL36 and UL55. Positively selected sites and functional domains were mapped onto HSV-1 proteins, as in Figure 2 and 3. For UL36, given the extended length of the protein sequence, positively selected sites were reported in the enlargement below. Supplementary Tables: Supplementary Table S1. List of viral genome sequences Supplementary Table S2. Herpes simplex genes excluded from the branch-sites analysis Supplementary Table S3. List of analyzed genes and dN/dS values Supplementary Table S4. Likelihood ratio test (LRT) statistics for models of variable selective pressure on the Hominin-infecting SVs branch. UL26 - Capsid scaffolding protein A379 Y374 S612 Interaction with Major Capsid protein assemblin cleavage sites UL29 - Major DNA-binding protein I878 Required for nuclear localization minimal DNA-binding region UL36 - Large tegument protein Deubiquitination Interaction with activity inner tegument protein (UL37) H2518 F2167 R2202 A2507 C1073 A1557 R1841 R2165G2198 S2488 D2506 W2573 K1052 T1103 R1702 F1746 Q1810 F1866 R2187 P2246 T2333 R2422 A2450 R2503 G2552 L2599 W2704 L3042 R3129 Tandem C-terminus repeats UL55 - Nuclear protein UL55 E99 Figure S1. Posi�ve selec�on in UL26, UL29, UL36 and UL55. Posi�vely selected sites and func�onal domains were mapped onto HSV-1 proteins, as in Figure 2 and 3. For UL36, given the extended length of the protein sequence, posi�vely selected sites were reported in the enlargement below. Supplementary Table S1. List of viral genome sequences. Accession Virus name Strain Name Virus Species Host Country ID (Common name; Strain abbreviation) Human herpesvirus 1 2016-1040 MG999886 Human alphaherpesvirus 1 Homo Sapiens USA (Herpes simplex virus 1; HSV-1 2016-1040) Human herpesvirus 1 HSV-H12113 MH999842 Human alphaherpesvirus 1 Homo Sapiens Finland (Herpes simplex virus 1; HSV-1 H12113) Human herpesvirus 1 HSV-H1412 MH999851 Human alphaherpesvirus 1 Homo Sapiens Finland (Herpes simplex virus 1; HSV-1 H1412) Human herpesvirus 1 172/2010 LT594105 Human alphaherpesvirus 1 Homo Sapiens Germany (Herpes simplex virus 1; HSV-1 172/2010) Human herpesvirus 1 HSV-1/0116209/India/2011 KJ847330 Human alphaherpesvirus 1 Homo Sapiens India (Herpes simplex virus 1; HSV-1/0116209/India/2011) Human herpesvirus 1 CJ394 JN420340 Human alphaherpesvirus 1 Homo Sapiens USA (Herpes simplex virus 1; HSV-1 CJ394) Human herpesvirus 1 CR38 HM585508 Human alphaherpesvirus 1 Homo Sapiens China (Herpes simplex virus 1; HSV-1 CR38) Human herpesvirus 1 E06 HM585496 Human alphaherpesvirus 1 Homo Sapiens Kenya (Herpes simplex virus 1; HSV-1 E06) Human herpesvirus 1 E07 HM585497 Human alphaherpesvirus 1 Homo Sapiens Kenya (Herpes simplex virus 1; HSV-1 E07) Human herpesvirus 1 E08 HM585498 Human alphaherpesvirus 1 Homo Sapiens Kenya (Herpes simplex virus 1; HSV-1 E08) Human herpesvirus 1 E13 HM585502 Human alphaherpesvirus 1 Homo Sapiens Kenya (Herpes simplex virus 1; HSV-1 E13) Human herpesvirus 1 H166 KM222726 Human alphaherpesvirus 1 Homo Sapiens USA (Herpes simplex virus 1; HSV-1 H166) Human herpesvirus 1 R11 HM585514 Human alphaherpesvirus 1 Homo Sapiens South Korea (Herpes simplex virus 1; HSV-1 R11) Human herpesvirus 1 S23 HM585512 Human alphaherpesvirus 1 Homo Sapiens Japan (Herpes simplex virus 1; HSV-1 S23) Human herpesvirus 1 CJ360 * JN420339 Human alphaherpesvirus 1 Homo Sapiens USA (Herpes simplex virus 1; HSV-1 CJ360) Human herpesvirus 2 2003-16029 KX574903 Human alphaherpesvirus 2 Homo Sapiens USA (Herpes simplex virus 2; HSV-2 2003-16029) Human herpesvirus 2 2004-4373 KX574861 Human alphaherpesvirus 2 Homo Sapiens Peru (Herpes simplex virus 2; HSV-2 2004-4373) Human herpesvirus 2 2006-30937 KX574866 Human alphaherpesvirus 2 Homo Sapiens Peru (Herpes simplex virus 2; HSV-2 2006-30937) Human herpesvirus 2 2006-49895 KX574868 Human alphaherpesvirus 2 Homo Sapiens USA (Herpes simplex virus 2; HSV-2 2006-49895) Human herpesvirus 2 2007-38120 KX574871 Human alphaherpesvirus 2 Homo Sapiens Zimbawe (Herpes simplex virus 2; HSV-2 2007-38120) Human herpesvirus 2 2007-38627 KX574874 Human alphaherpesvirus 2 Homo Sapiens Peru (Herpes simplex virus 2; HSV-2 2007-38627) Human herpesvirus 2 2007-39712 * KX574880 Human alphaherpesvirus 2 Homo Sapiens South africa (Herpes simplex virus 2; HSV-2 2007-39712) Human herpesvirus 2 2009-13458 KX574889 Human alphaherpesvirus 2 Homo Sapiens USA (Herpes simplex virus 2; HSV-2 2009-13458) Human herpesvirus 2 2009-3532 KX574892 Human alphaherpesvirus 2 Homo Sapiens South africa (Herpes simplex virus 2; HSV-2 2009-3532) Human herpesvirus 2 2009-4556 KX574894 Human alphaherpesvirus 2 Homo Sapiens Kenya (Herpes simplex virus 2; HSV-2 2009-4556) Human herpesvirus 2 2011-21761 KX574897 Human alphaherpesvirus 2 Homo Sapiens USA (Herpes simplex virus 2; HSV-2 2011-21761) Human herpesvirus 2 HSV2-H1227 KY922721 Human alphaherpesvirus 2 Homo Sapiens Finland (Herpes simplex virus 2; HSV-2 H1227) Human herpesvirus 2 HSV2-H1229 KY922722 Human alphaherpesvirus 2 Homo Sapiens Finland (Herpes simplex virus 2; HSV-2 H1229) Human herpesvirus 2 2008_15116 MF621257 Human alphaherpesvirus 2 Homo Sapiens Kenya (Herpes simplex virus 2; HSV-2 2008_15116) Human herpesvirus 2 CNS15 MK105998 Human alphaherpesvirus 2 Homo Sapiens USA (Herpes simplex virus 2; HSV-2 CNS15) Chimpanzee alpha-1 herpesvirus 105640 * NC_023677 Panine alphaherpesvirus 3 Pan troglodytes USA (Chimpanzee herpesvirus; ChHV 105640) Macacine herpesvirus 1 12930 KY628971 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 12930) Macacine herpesvirus 1 1504-11 KY628969 Macacine alphaherpesvirus 1 Macaca nemestrina USA (B virus; McHV-1 1504-11) Macacine herpesvirus 1 16293 KY628972 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 16293) Macacine herpesvirus 1 20620 KY628973 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 20620) Macacine herpesvirus 1 24105-G KY628974 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 24105-G) Macacine herpesvirus 1 26896-G KY628975 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 26896-G) Macacine herpesvirus 1 31618-G KY628978 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 31618-G) Macacine herpesvirus 1 32425-G KY628981 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 32425-G) 7709642 KY628982 Macacine herpesvirus 1 Macacine alphaherpesvirus 1 Macaca silenus USA (B virus; McHV-1 7709642) Macacine herpesvirus 1 8100812 KY628968 Macacine alphaherpesvirus 1 Macaca silenus USA (B virus; McHV-1 8100812) Macacine herpesvirus 1 9400371 KY628983 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 9400371) Macacine herpesvirus 1 E90-136 KJ566591 Macacine alphaherpesvirus 1 Macaca fascicularis USA (B virus; McHV-1 E90-136) Macacine herpesvirus 1 KQ KY628970 Macacine alphaherpesvirus 1 Macaca nemestrina USA (B virus; McHV-1 KQ) Macacine herpesvirus 1 M12-O KY628985 Macacine alphaherpesvirus 1 Macaca radiata USA (B virus; McHV-1 M12-O) Macacine herpesvirus 1 E2490 * NC_004812 Macacine alphaherpesvirus 1 Macaca mulatta USA (B virus; McHV-1 E2490) Papiine herpesvirus 2 A189164 KF908239 Papiine alphaherpesvirus 2 - USA (Herpesvirus papio 2, PaHV-2 A189164) Papiine herpesvirus 2 A951 KF908242 Papiine alphaherpesvirus 2 - USA (Herpesvirus papio 2; PaHV-2 A951) Papiine herpesvirus 2 OU2-5 KF908241 Papiine alphaherpesvirus 2 Papio anubis USA (Herpesvirus papio 2; PaHV-2 OU2-5) Papiine herpesvirus 2 OU4-2 KF908244 Papiine alphaherpesvirus 2 Papio ursinus USA (Herpesvirus papio 2; PaHV-2 OU4-2) Papiine herpesvirus 2 OU4-8 KF908243 Papiine alphaherpesvirus 2 Papio ursinus USA (Herpesvirus papio 2; PaHV-2 OU4-8) Papiine herpesvirus 2 X313 * NC_007653 Papiine alphaherpesvirus 2 Papio anubis USA (Herpesvirus papio 2; PaHV-2 X313) Cercopithecine herpesvirus 2 Cercopithecine Cercopithecus SA8 * NC_006560 - (Simian agent 8; CeHV-2 SA8) alphaherpesvirus 2 aethiops Note: * strains used for SLAC analysis. Supplementary Table S2. Herpes simplex genes excluded from the branch-sites analysis. Gene Name Motivation UL15 Overlapping ORFs UL16 Overlapping ORFs UL17 Overlapping ORFs UL26.5 Overlapping ORFs US4 Excessive divergence and length among sequences US11 Overlapping ORFs RL1 Duplicated genes/no reliable orthologs RL2 Duplicated genes/no reliable orthologs RS1 Duplicated genes/no reliable orthologs Supplementary Table S3. List of analyzed genes and dN/dS values Gene Symbol Protein Product Name dN/dS UL1 * Envelope glycoprotein L 0.219 UL2 * Uracil-DNA glycosylase 0.106 UL3 Nuclear protein UL3 0.174 UL5 * DNA replication helicase 0.0876 UL4 Nuclear protein UL4 0.182 UL6 * Capsid portal protein 0.144 UL7 * Cytoplasmic envelopment protein 1 0.188 UL9 * DNA replication origin-binding protein 0.129 UL8 * DNA helicase/primase complex-associated protein 0.226 UL10 * Envelope glycoprotein M 0.196 UL12 * Alkaline nuclease 0.206 UL11 * Cytoplasmic envelopment protein 3 0.267 UL14 * Tegument protein UL14 0.242 UL13 Serine/threonine-protein kinase UL13 0.172 UL18 * Triplex capsid protein 2 0.0933 UL20 Envelope protein UL20 0.162 UL19* Major capsid protein 0.0827 UL21 * Tegument protein UL21 0.15 UL22 * Envelope glycoprotein H 0.195 UL23 * Thymidine kinase 0.234 UL24 Nuclear protein UL24 0.153 UL25 * Capsid vertex
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,993,581 B2 Perrine Et Al
    US00899.3581B2 (12) United States Patent (10) Patent No.: US 8,993,581 B2 Perrine et al. (45) Date of Patent: Mar. 31, 2015 (54) METHODS FOR TREATINGVIRAL (58) Field of Classification Search DSORDERS CPC ... A61K 31/00; A61K 31/166; A61K 31/185: A61K 31/233; A61K 31/522: A61K 38/12: (71) Applicant: Trustees of Boston University, Boston, A61K 38/15: A61K 45/06 MA (US) USPC ........... 514/263.38, 21.1, 557, 565, 575, 617; 424/2011 (72) Inventors: Susan Perrine, Weston, MA (US); Douglas Faller, Weston, MA (US) See application file for complete search history. (73) Assignee: Trustees of Boston University, Boston, (56) References Cited MA (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 3,471,513 A 10, 1969 Chinn et al. patent is extended or adjusted under 35 3,904,612 A 9/1975 Nagasawa et al. U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 13/915,092 FOREIGN PATENT DOCUMENTS (22) Filed: Jun. 11, 2013 CA 1209037 A 8, 1986 CA 2303268 A1 4f1995 (65) Prior Publication Data (Continued) US 2014/OO45774 A1 Feb. 13, 2014 OTHER PUBLICATIONS Related U.S. Application Data (63) Continuation of application No. 12/890,042, filed on PCT/US 10/59584 Search Report and Written Opinion mailed Feb. Sep. 24, 2010, now abandoned. 11, 2011. (Continued) (60) Provisional application No. 61/245,529, filed on Sep. 24, 2009, provisional application No. 61/295,663, filed on Jan. 15, 2010. Primary Examiner — Savitha Rao (74) Attorney, Agent, or Firm — Nixon Peabody LLP (51) Int.
    [Show full text]
  • (Epstein- Barr Virus) No Líquido Cefalorraquidiano De Crianças Com Suspeita De Meningoencefalite No Estado De Minas
    1 Universidade Federal de Minas Gerais Programa de Pós-Graduação em Microbiologia Detecção de human gammaherpesvirus 4 (Epstein- Barr virus) no líquido cefalorraquidiano de crianças com suspeita de meningoencefalite no estado de Minas Gerais Belo Horizonte 2020 2 NATHALIA MARTINS QUINTÃO Detecção de human gammaherpesvirus 4 (Epstein- Barr virus - EBV) no líquido cefalorraquidiano de crianças com suspeita de meningoencefalite no estado de Minas Gerais Dissertação de mestrado apresentada ao Programa de Pós-Graduação em Microbiologia do Instituto de Ciências Biológicas da Universidade Federal de Minas Gerais, como requisito à obtenção do título de Mestre em Microbiologia. Orientadora: Prof.ª. Dr.ª Erna Gessien Kroon Belo Horizonte 2020 3 4 5 RESUMO Epstein-Barr virus pertence à subfamília Gammaherpesvirinae da família Herpesviridae e é o agente etiológico da mononucleose infecciosa. A transmissão de EBV geralmente é pela saliva, sendo o quadro clássico de infecção primária a mononucleose apenas 5% dos casos evoluem para quadros de meningoencefalites. Os grupos de risco são principalmente crianças na primeira infância e pacientes imunocomprometidos. No Brasil, nos últimos 10 anos foram registrados aproximadamente 22 mil casos de meningites e encefalites virais, sendo 52% dos casos em crianças com até 14 anos de idade. O ensaio de PCR em tempo real (qPCR) revoluciona o diagnóstico de neuroinfecções virais. O objetivo deste trabalho foi detectar a presença de DNA genômico e de mRNA de EBV por qPCR para casos de meningoencefalites em pacientes de Minas Gerais e construir, com base na análise de prontuário dos pacientes e dados disponíveis no DATASUS, um breve panorama dos casos de meningoencefalites por EBV.
    [Show full text]
  • Shared Ancestry of Herpes Simplex Virus 1 Strain Patton with Recent Clinical Isolates from Asia and with Strain KOS63
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Virology Manuscript Author . Author manuscript; Manuscript Author available in PMC 2018 December 01. Published in final edited form as: Virology. 2017 December ; 512: 124–131. doi:10.1016/j.virol.2017.09.016. Shared ancestry of herpes simplex virus 1 strain Patton with recent clinical isolates from Asia and with strain KOS63 Aldo Pourcheta, Richard Copinb, Matthew C. Mulveyc, Bo Shopsina,b, Ian Mohra, and Angus C. Wilsona,# aDepartment of Microbiology, New York University School of Medicine, New York, New York, USA bDepartment of Medicine, New York University School of Medicine, New York, New York, USA cBeneVir Biopharm, Inc., Gaithersburg, Maryland, USA Abstract Herpes simplex virus 1 (HSV-1) is a widespread pathogen that persists for life, replicating in surface tissues and establishing latency in peripheral ganglia. Increasingly, molecular studies of latency use cultured neuron models developed using recombinant viruses such as HSV-1 GFP- US11, a derivative of strain Patton expressing green fluorescent protein (GFP) fused to the viral US11 protein. Visible fluorescence follows viral DNA replication, providing a real time indicator of productive infection and reactivation. Patton was isolated in Houston, Texas, prior to 1973, and distributed to many laboratories. Although used extensively, the genomic structure and phylogenetic relationship to other strains is poorly known. We report that wild type Patton and the GFP-US11 recombinant contain the full complement of HSV-1 genes and differ within the unique regions at only eight nucleotides, changing only two amino acids. Although isolated in North America, Patton is most closely related to Asian viruses, including KOS63.
    [Show full text]
  • Supplementary Material
    SUPPLEMENTARY MATERIAL Appendix; Search strategy MEDLINE 1. Herpes Labialis/ 2. Stomatitis, Herpetic/ 3. ((herpe* adj3 (labial* or stomatiti* or gingivostomatiti*)) or cold-sore* or fever-blister*).tw,kf. 4. 1 or 2 or 3 5. Herpes Simplex/ 6. Simplexvirus/ or herpesvirus 1, human/ or herpesvirus 2, human/ 7. (hsv-1 or hsv1 or hsv-2 or hsv2 or simplexvirus or simplex-virus or herpes-simplex or herpe*).tw,kf. 8. exp Mouth/ 9. (lip*1 or mouth or labial* or orolabial* or oro-labial* or perioral or peri-oral or extraoral or extra-oral or intraoral or intra-oral or gingiva* or gingivo*).tw,kf. 10. (5 or 6 or 7) and (8 or 9) 11. 4 or 10 12. Secondary Prevention/ 13. exp Recurrence/ 14. (prevention or recurren* or prophyla*).tw,kf. 15. pc.fs. 16. 12 or 13 or 14 or 15 17. 11 and 16 18. exp animals/ not human*.sh. 19. 17 not 18 EMBASE 1. herpes labialis/ 2. herpetic stomatitis/ 3. ((herpe* adj3 (labial* or stomatiti* or gingivostomatiti*)) or cold-sore* or fever-blister*).tw,kw,dq. 4. 1 or 2 or 3 5. herpes simplex/ 6. simplexvirus/ or exp human alphaherpesvirus 1/ or exp herpes simplex virus 2/ 7. (hsv-1 or hsv1 or hsv-2 or hsv2 or simplexvirus or simplex-virus or herpes-simplex or herpe*).tw,kw,dq. 8. mouth/ or exp cheek/ or exp lip/ or exp mouth cavity/ or exp mouth floor/ or exp mouth mucosa/ or exp palate/ or oral blister/ 9. (lip*1 or mouth or labial* or orolabial* or oro-labial* or perioral or peri-oral or extraoral or extra-oral or intraoral or intra-oral or gingiva* or gingivo*).tw,kw,dq.
    [Show full text]
  • (Title of the Thesis)*
    INVESTIGATING THE ROLES OF HERPES SIMPLEX VIRUS TYPE 2 PROTEINS UL21 AND US3 IN REGULATION OF THE NUCLEAR EGRESS COMPLEX by Jamil H. Muradov A thesis submitted to the Graduate Program in Microbiology and Immunology in the Department of Biomedical and Molecular Sciences In conformity with the requirements for the degree of Master of Sciences Queen’s University Kingston, Ontario, Canada (May, 2021) Copyright © Jamil H. Muradov, 2021 Abstract Herpes Simplex Virus 2 (HSV-2) nuclear egress is mediated by viral nuclear egress complex (NEC) proteins, pUL31 and pUL34, found at the inner nuclear membrane of infected cells (INM). Nuclear egress requires successful primary envelopment of a capsid at the INM, budding of the resulting capsid-containing vesicle into the perinuclear space (PNS), de-envelopment of the perinuclear virion at the outer nuclear membrane and release of the capsid into the cytoplasm. In this work, we demonstrate that HSV-2 pUL31 and pUL34 are phosphorylated by a viral protein kinase, called pUs3, which serves to prevent excessive INM deformation and accumulation of the primary enveloped virions (PEVs) in PNS after successful primary envelopment of capsids. It was found that a tegument protein, pUL21, modulates pUs3 dependent pUL31 and pUL34 phosphorylation. We also determined that in UL21-knockout infected cells, pUs3 is differentially modified, and this modification is likely an autophosphorylation. Higher levels of pUs3 phosphorylation were shown to result in augmentation of pUs3/PKA substrate phosphorylation levels, including pUL31 and pUL34. Excessive phosphorylation of the NEC components caused their aberrant distribution at the INM, extravagation of the nuclear envelope and failure of the capsids to undergo primary envelopment at the INM.
    [Show full text]
  • The Critical Role of Genome Maintenance Proteins in Immune Evasion During Gammaherpesvirus Latency
    fmicb-09-03315 January 4, 2019 Time: 17:18 # 1 REVIEW published: 09 January 2019 doi: 10.3389/fmicb.2018.03315 The Critical Role of Genome Maintenance Proteins in Immune Evasion During Gammaherpesvirus Latency Océane Sorel1,2 and Benjamin G. Dewals1* 1 Immunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine-FARAH, University of Liège, Liège, Belgium, 2 Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, United States Gammaherpesviruses are important pathogens that establish latent infection in their natural host for lifelong persistence. During latency, the viral genome persists in the nucleus of infected cells as a circular episomal element while the viral gene expression program is restricted to non-coding RNAs and a few latency proteins. Among these, the genome maintenance protein (GMP) is part of the small subset of genes expressed in latently infected cells. Despite sharing little peptidic sequence similarity, gammaherpesvirus GMPs have conserved functions playing essential roles in latent Edited by: Michael Nevels, infection. Among these functions, GMPs have acquired an intriguing capacity to evade University of St Andrews, the cytotoxic T cell response through self-limitation of MHC class I-restricted antigen United Kingdom presentation, further ensuring virus persistence in the infected host. In this review, we Reviewed by: Neil Blake, provide an updated overview of the main functions of gammaherpesvirus GMPs during University of Liverpool, latency with an emphasis on their immune evasion properties. United Kingdom James Craig Forrest, Keywords: herpesvirus, viral latency, genome maintenance protein, immune evasion, antigen presentation, viral University of Arkansas for Medical proteins Sciences, United States *Correspondence: Benjamin G.
    [Show full text]
  • Repurposing the Human Immunodeficiency Virus (Hiv) Integrase
    REPURPOSING THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTEGRASE INHIBITOR RALTEGRAVIR FOR THE TREATMENT OF FELID ALPHAHERPESVIRUS 1 (FHV-1) OCULAR INFECTION A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Matthew Robert Pennington August 2018 © 2018 Matthew Robert Pennington REPURPOSING THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTEGRASE INHIBITOR RALTEGRAVIR FOR THE TREATMENT OF FELID ALPHAHERPESVIRUS 1 (FHV-1) OCULAR INFECTION Matthew Robert Pennington, Ph.D. Cornell University 2018 Herpesviruses infect many species, inducing a wide range of diseases. Herpesvirus- induced ocular disease, which may lead to blindness, commonly occurs in humans, dogs, and cats, and is caused by human alphaherpesvirus 1 (HHV-1), canid alphaherpesvirus (CHV-1), and felid alphaherpesvirus 1 (FHV-1), respectively. Rapid and effective antiviral therapy is of the utmost importance to control infection in order to preserve the vision of infected people or animals. However, current treatment options are suboptimal, in large part due to the difficulty and cost of de novo drug development and the lack of effective models to bridge work in in vitro cell cultures and in vivo. Repurposing currently approved drugs for viral infections is one strategy to more rapidly identify new therapeutics. Furthermore, studying ocular herpesviruses in cats is of particular importance, as this condition is a frequent disease manifestation in these animals and FHV-1 infection of the cat is increasingly being recognized as a valuable natural- host model of herpesvirus-induced ocular infection First, the current models to study ocular herpesvirus infections were reviewed.
    [Show full text]
  • Hampering Herpesviruses HHV-1 and HHV-2 Infection by Extract of Ginkgo Biloba (Egb) and Its Phytochemical Constituents
    fmicb-10-02367 October 12, 2019 Time: 11:50 # 1 ORIGINAL RESEARCH published: 15 October 2019 doi: 10.3389/fmicb.2019.02367 Hampering Herpesviruses HHV-1 and HHV-2 Infection by Extract of Ginkgo biloba (EGb) and Its Phytochemical Constituents Marta Sochocka1*, Maciej Sobczynski´ 2, Michał Ochnik1, Katarzyna Zwolinska´ 1 and Jerzy Leszek3 1 Laboratory of Virology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland, 2 Department of Genomics, Faculty of Biotechnology, University of Wrocław, Wrocław, Poland, 3 Department of Psychiatry, Wrocław Medical University, Wrocław, Poland Despite the availability of several anti-herpesviral agents, it should be emphasized that the need for new inhibitors is highly encouraged due to the increasing resistant viral strains as well as complications linked with periods of recurring viral replication and reactivation of latent herpes infection. Extract of Ginkgo biloba (EGb) is a common phytotherapeutics around the world with health benefits. Limited studies, however, have addressed the potential antiviral activities of EGb, including herpesviruses such as Human alphaherpesvirus 1 (HHV-1) and Human alphaherpesvirus 2 (HHV-2). We Edited by: Anthony Nicola, evaluated the antiviral activity of EGb and its phytochemical constituents: flavonoids Washington State University, and terpenes against HHV-1 and HHV-2. Pretreatment of the herpesviruses with EGb United States prior to infection of cells produced a remarkable anti-HHV-1 and anti-HHV-2 activity. Reviewed by: The extract affected the viruses before adsorption to cell surface at non-cytotoxic Konstantin Kousoulas, Louisiana State University, concentrations. In this work, through a comprehensive anti-HHV-1 and anti-HHV-2 United States activity study, it was revealed that flavonoids, especially isorhamnetin, are responsible Oren Kobiler, Tel Aviv University, Israel for the antiviral activity of EGb.
    [Show full text]
  • Commission Directive (Eu)
    L 279/54 EN Offi cial Jour nal of the European Union 31.10.2019 COMMISSION DIRECTIVE (EU) 2019/1833 of 24 October 2019 amending Annexes I, III, V and VI to Directive 2000/54/EC of the European Parliament and of the Council as regards purely technical adjustments THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (1), and in particular Article 19 thereof, Whereas: (1) Principle 10 of the European Pillar of Social Rights (2), proclaimed at Gothenburg on 17 November 2017, provides that every worker has the right to a healthy, safe and well-adapted working environment. The workers’ right to a high level of protection of their health and safety at work and to a working environment that is adapted to their professional needs and that enables them to prolong their participation in the labour market includes protection from exposure to biological agents at work. (2) The implementation of the directives related to the health and safety of workers at work, including Directive 2000/54/EC, was the subject of an ex-post evaluation, referred to as a REFIT evaluation. The evaluation looked at the directives’ relevance, at research and at new scientific knowledge in the various fields concerned. The REFIT evaluation, referred to in the Commission Staff Working Document (3), concludes, among other things, that the classified list of biological agents in Annex III to Directive 2000/54/EC needs to be amended in light of scientific and technical progress and that consistency with other relevant directives should be enhanced.
    [Show full text]
  • Medical Microbiology, Virology & Immunology
    I.I. Generalov MEDICAL MICROBIOLOGY, VIROLOGY & IMMUNOLOGY Part 2 Medical Bacteriology & Medical Virology Lecture Course for Students of Medical Universities VITEBSK STATE MEDICAL UNIVERSITY 2016 Ministry of Health of the Republic of Belarus Higher Educational Establishment “Vitebsk State Order of Peoples' Friendship Medical University” I.I. Generalov MEDICAL MICROBIOLOGY, VIROLOGY & IMMUNOLOGY Part 2 Medical Bacteriology & Medical Virology Lecture Course for Students of Medical Universities VITEBSK 2016 2 УДК [579+616.31]=111(07) ББК 52.64 я73+56.6 я73 Г 34 Printed according to the decision of Educational&Methodological Consociation on Medical Education (July 1, 2016) Reviewed by: D.V.Tapalsky, MD, PhD, Head of Microbiology, Virology and Immunology Dpt, Gomel State Medical University Microbiology, Virology and Immunology Dpt, Belarusian State Medical University, Minsk Generalov I.I. Г 34 Medical Microbiology, Virology and Immunology. Part 2. Medical Bacteriology & Medical Virology – Lecture Course for students of medical universities / I.I. Generalov. – Vitebsk, - VSMU. - 2016. - 392 p. ISBN 978-985-466-743-0 The Lecture Course on Medical Microbiology, Virology and Immunology accumulates a broad scope of data covering the most of essential areas of medical microbiology. The textbook is composed according to the educational standard, plan and program, approved by Ministry of Education and Ministry of Health of the Republic of Belarus. This edition encompasses all basic sections of the subject – General Microbiology, Medical Immunology, Medical Bacteriology and Virology. Part 2 of the Lecture Course comprises Medical Bacteriology and Medical Virology sections. The book is directed for students of General Medicine faculties and Dentistry faculties of higher educational establishments. УДК [579+616.31]=111(07) ББК 52.64 я73+56.6 я73 © Generalov I.I., 2016 © VSMU Press, 2016 ISBN 978-985-466-743-0 3 CONTENTS Pages Abbreviation list 5 Section 1.
    [Show full text]
  • The Cyclin-Dependent Kinase 5 Inhibitor Peptide Inhibits Herpes Simplex Virus Type 1 Replication
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2019 The cyclin-dependent kinase 5 inhibitor peptide Inhibits herpes simplex virus type 1 replication Man, Adrian ; Slevin, Mark ; Petcu, Eugen ; Fraefel, Cornel Abstract: In order to evaluate the influence of CDK5 inhibitory peptide (CIP) on Human alphaher- pesvirus 1 (HSV-1) replication, we constructed two recombinant adeno-associated-virus 2 (rAAV2) vec- tors encoding CIP fused with cyan-fluorescent-protein (CFP), with or without nuclear localization signal. A third vector encoding non-fused CIP and CFP was also constructed. HeLa and HEK 293T cells were infected with the rAAV-CIP vectors at multiplicity of infection (MOI) of 5000, in the absence or presence of a recombinant HSV-1 that encodes a yellow-fluorescent-protein (rHSV48Y; MOI = 1). Cells co-infected with rHSV48Y and rAAV vectors that did not express the CIP gene (rAAV-CFP-Neo) served as controls. At 24 h after infection, the effect of CIP on rHSV48Y replication was assessed by PCR, qRT-PCR, Western-blot, flow-cytometry, epifluorescence and confocal microscopy. We show that in cultures co-infected with rAAV-CFP-Neo, 27% of the CFP-positive cells present rHSV48Y replication compartments. By contrast, in cultures co-infected with CIP-encoding rAAV2 vectors and rHSV48Y only 6-20% of the cells positive for CIP showed rHSV48Y replication compartments, depending on the CIP variant. Flow-cytometry showed that less than 40% of the rHSV48Y/rAAV-CIP, and more than 75% of rHSV48Y/rAAV-CFP-Neo co-infected cells were positive for both transgene products.
    [Show full text]
  • B Directive 2000/54/Ec of the European
    02000L0054 — EN — 24.06.2020 — 002.001 — 1 This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document ►B DIRECTIVE 2000/54/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1) of Directive 89/391/EEC) (OJ L 262, 17.10.2000, p. 21) Amended by: Official Journal No page date ►M1 Commission Directive (EU) 2019/1833 of 24 October 2019 L 279 54 31.10.2019 ►M2 Commission Directive (EU) 2020/739 of 3 June 2020 L 175 11 4.6.2020 02000L0054 — EN — 24.06.2020 — 002.001 — 2 ▼B DIRECTIVE 2000/54/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1) of Directive 89/391/EEC) CHAPTER I GENERAL PROVISIONS Article 1 Objective 1. This Directive has as its aim the protection of workers against risks to their health and safety, including the prevention of such risks, arising or likely to arise from exposure to biological agents at work.
    [Show full text]